Skip Navigation


Hum. Reprod. Advance Access originally published online on October 23, 2008
Human Reproduction 2008 23(12):2626-2628; doi:10.1093/humrep/den376
This Article
Right arrow Full Text
Right arrow Full Text (PDF )
Right arrow All Versions of this Article:
23/12/2626    most recent
den376v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Mastenbroek, S.
Right arrow Articles by Repping, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mastenbroek, S.
Right arrow Articles by Repping, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

What next for preimplantation genetic screening? More randomized controlled trials needed?

S. Mastenbroek1,6, P. Scriven2, M. Twisk1, S. Viville3,4,5, F. Van der Veen1 and S. Repping1

1 Center for Reproductive Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands 2 Center for Preimplantation Genetic Diagnosis, Department of Cytogenetics, Guy's and St Thomas' NHS Foundation Trust, London, UK 3 Service de Biologie de la Reproduction–Syndicat Inter-Hospitalier de la Communauté Urbaine de Strasbourg, Centre Médico-Chirurgical et Obstétrical, Service de Biologie, Schiltigheim, France 4 Department of Developmental Biology, Institut de Génétique et de Biologie Moléculaire et Cellulaire, Illkirch, France 5 Faculté de Médecine, Centre Hospitalier Universitaire, Université Louis Pasteur, Strasbourg, France

6 Correspondence address. Tel: +31-20-5663090; E-mail: s.mastenbroek{at}amc.uva.nl

The recent debate on preimplantation genetic screening (PGS) has raised questions about its routine use in clinical practice. It has been suggested that the most effective way to resolve the debate about the usefulness of PGS is to perform more well-designed and well-executed randomized controlled trials (RCTs). However, in view of the lack of evidence for the effectiveness of PGS and the accumulating evidence for its harmfulness, it is our opinion that it is unethical to perform additional RCTs for the indication advanced maternal age using cleavage stage biopsy.

Key words: PGS/ethics/clinical practice

Submitted on July 8, 2008; resubmitted on August 19, 2008; accepted on September 1, 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Hum ReprodHome page
E. R. Hernandez
What next for preimplantation genetic screening? Beyond aneuploidy
Hum. Reprod., July 1, 2009; 24(7): 1538 - 1541.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
M. A. Fritz
Perspectives on the efficacy and indications for preimplantation genetic screening: where are we now?
Hum. Reprod., December 1, 2008; 23(12): 2617 - 2621.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.